Predicting Radiotherapy and Chemotherapy Response
| Period from: | 2008-10-15 to 2009-10-14 |
| Principal Investigators: | Dr. Mario Chevrette |
| Co-Investigators: | Armen G. Aprikian, Gerald Batist, Fabio L.B. Cury, Anne-Marie Mes-Masson, John S. Sampalis |
| Institution: | McGill University Health Centre |
| Department: | Urology |
| Partner: | Canadian Partnership Against Cancer Corporation |
| Program: | Pilot Research Project |
| Abstract: |
Although chemotherapy and radiotherapy are used for many types of advanced stages of cancer, there are no reliable markers that can stratify the patients that will better benefit from such treatments. We accumulated evidence that expression of CD9 and its protein partners could represent such new prognostic markers. Thus, the main goal of this pilot project is to determine if the expression of CD9 and its partners could predict the response to microtubule-targeted chemotherapeutic agents and/or radiotherapy.
This will be accomplished by:
- first, generating and analyzing antibodies against one CD9 partner;
- second, confirming that CD9 and its partners sensitize prostate and ovarian cancer cells to microtubule-targeted chemotherapeutic agents or radiotherapy; and
- third, by correlating the expression of CD9 and its partners to the clinical response of patients that underwent either radiotherapy (prostate cancer) or microtubule-directed chemotherapy (both prostate and ovarian cancers).
Since CD9 is down-regulated in many cancer types, there could be an important number of patients that could benefit from this project.
|
|
 |
